More Cancer Patients Are Opting to Preserve Their TumorsNew Tumor-Preservation Service Opens in Arizona, Giving Patients the Opportunity to Preserve Unadulterated Tumor Tissue for Potential Personalized Cancer Immunotherapy
Internationally Recognized Johns Hopkins Oncologist Dr. Stephen J. Noga Joins Immunocine as Chief Medical OfficerVeteran Physician-Scientist and Cellular Therapy Expert to Help Advance the Future of Personalized Cancer Immunotherapy
Immunocine Cancer Center Appoints Vita S. Salsman as Executive DirectorImmunocine Cancer Center today announced the appointment of Vita S. Salsman as Executive Director. Salsman brings more than two decades of experience in cancer immunotherapy, cell therapy manufacturing, and translational medicine to support the organization’s continued growth and advancement of personalized cancer immunotherapy. Salsman has built her career advancing innovative therapies from early scientific discovery through clinical application, with expertise spanning cell therapy manufacturing, clinical operations, quality systems, regulatory strategy, and translational medicine.
